Report Information More information from: https ://www.wis eguyreports .com/reports /495873
Retinal Vein Occlusion - Pipeline Review, H1 2016 Report / Search Code: WGR495873
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Retinal Vein Occlus ion - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Retinal Vein Occlus ion - Pipeline Review, H1 2016’, provides an overview of the Retinal Vein Occlus ion pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Retinal Vein Occlus ion, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlus ion and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Retinal Vein Occlus ion - The report reviews pipeline therapeutics for Retinal Vein Occlus ion by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Retinal Vein Occlus ion therapeutics and enlis ts all their major and minor projects - The report as s es s es Retinal Vein Occlus ion therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Retinal Vein Occlus ion Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Retinal Vein Occlus ion - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics
- Devis e corrective meas ures for pipeline projects by unders tanding Retinal Vein Occlus ion pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Retinal Vein Occlus ion Overview 7 Therapeutics Development 8 Pipeline Products for Retinal Vein Occlus ion - Overview 8 Retinal Vein Occlus ion - Therapeutics under Development by Companies 9 Retinal Vein Occlus ion - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Retinal Vein Occlus ion - Products under Development by Companies 12 Retinal Vein Occlus ion - Companies Involved in Therapeutics Development 13 Aerpio Therapeutics , Inc. 13 Avalanche Biotechnologies , Inc. 14 EyeGate Pharmaceuticals , Inc. 15 Kala Pharmaceuticals , Inc. 16 Mabion SA 17 NicOx S.A. 18 Ohr Pharmaceutical Inc. 19 Precis ion Ocular Ltd 20 pSivida Corp. 21 ThromboGenics NV 22 Retinal Vein Occlus ion - Therapeutics As s es s ment 23 As s es s ment by Monotherapy Products 23 As s es s ment by Target 24 As s es s ment by Mechanis m of Action 26 As s es s ment by Route of Adminis tration 28 As s es s ment by Molecule Type 30 Drug Profiles 32 AKB-9778 - Drug Profile 32 Product Des cription 32 Mechanis m of Action 32 R& D Progres s 32 AVA-101 - Drug Profile 34 Product Des cription 34 Mechanis m of Action 34 R& D Progres s 34 dexamethas one acetate - Drug Profile 36 Product Des cription 36 Mechanis m of Action 36 R& D Progres s 36 Drugs for Retinal Dis eas es - Drug Profile 38 Product Des cription 38 Mechanis m of Action 38 R& D Progres s 38 fluocinolone acetonide SR - Drug Profile 39 Product Des cription 39 Mechanis m of Action 39 R& D Progres s 39 loteprednol etabonate - Drug Profile 41 Product Des cription 41 Mechanis m of Action 41 R& D Progres s 41 NCX-422 - Drug Profile 43 Product Des cription 43 Mechanis m of Action 43 R& D Progres s 43 NCX-434 - Drug Profile 44 Product Des cription 44 Mechanis m of Action 44 R& D Progres s 44 ocriplas min (recombinant) - Drug Profile 45 Product Des cription 45 Mechanis m of Action 45 R& D Progres s 45 ranibizumab bios imilar - Drug Profile 49
Product Des cription 49 Mechanis m of Action 49 R& D Progres s 49 s qualamine lactate - Drug ProďŹ le 50 Product Des cription 50 Mechanis m of Action 50 R& D Progres s 50 Retinal Vein Occlus ion - Recent Pipeline Updates 53 Retinal Vein Occlus ion - Dormant Projects 77 Retinal Vein Occlus ion - Dis continued Products 78 Retinal Vein Occlus ion - Product Development Miles tones 79 Featured News & Pres s Releas es 79 Nov 04, 2015: Alimera Sciences announces late breaking pres entation of new ILUVIEN Analys is During Retina Subs pecialty day at AAO annual meeting 2015 79 Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN 79 Jul 13, 2015: Ohr Pharmaceutical Announces Pos itive Res ults of a Phas e II Clinical Study for OHR-102 in Retinal Vein Occlus ion 80 Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlus ion 81 Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phas e II Clinical Data in Retinal Vein Occlus ion 82 Jul 31, 2014: Kala Pharmaceuticals Initiates Phas e 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlus ion and Diabetic Macular Edema 83 Aug 20, 2013: Ohr Pharmaceutical Announces Inves tigator Spons ored Trial of Squalamine Eye Drops in Retinal Vein Occlus ion 83 Dec 26, 2010: Alimera To Hold Conference Call To Dis cus s Complete Res pons e Letter Regarding NDA For ILUVIEN 84 Appendix 85 Methodology 85 Coverage 85 Secondary Res earch 85 Primary Res earch 85 Expert Panel Validation 85 Contact Us 85 Dis claimer 86 Lis t of Tables Number of Products under Development for Retinal Vein Occlus ion, H1 2016 8 Number of Products under Development by Companies , H1 2016 9 Comparative Analys is by Clinical Stage Development, H1 2016 10 Comparative Analys is by Early Stage Development, H1 2016 11 Products under Development by Companies , H1 2016 12 Retinal Vein Occlus ion - Pipeline by Aerpio Therapeutics , Inc., H1 2016 13 Retinal Vein Occlus ion - Pipeline by Avalanche Biotechnologies , Inc., H1 2016 14 Retinal Vein Occlus ion - Pipeline by EyeGate Pharmaceuticals , Inc., H1 2016 15 Retinal Vein Occlus ion - Pipeline by Kala Pharmaceuticals , Inc., H1 2016 16 Retinal Vein Occlus ion - Pipeline by Mabion SA, H1 2016 17 Retinal Vein Occlus ion - Pipeline by NicOx S.A., H1 2016 18 Retinal Vein Occlus ion - Pipeline by Ohr Pharmaceutical Inc., H1 2016 19 Retinal Vein Occlus ion - Pipeline by Precis ion Ocular Ltd, H1 2016 20 Retinal Vein Occlus ion - Pipeline by pSivida Corp., H1 2016 21 Retinal Vein Occlus ion - Pipeline by ThromboGenics NV, H1 2016 22 As s es s ment by Monotherapy Products , H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanis m of Action, H1 2016 27 Number of Products by Stage and Route of Adminis tration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Retinal Vein Occlus ion Therapeutics - Recent Pipeline Updates , H1 2016 53 Retinal Vein Occlus ion - Dormant Projects , H1 2016 77 Retinal Vein Occlus ion - Dis continued Products , H1 2016 78 Lis t of Figures Number of Products under Development for Retinal Vein Occlus ion, H1 2016 8 Number of Products under Development by Companies , H1 2016 9 Comparative Analys is by Clinical Stage Development, H1 2016 10 Comparative Analys is by Early Stage Products , H1 2016 11 As s es s ment by Monotherapy Products , H1 2016 23 Number of Products by Top 10 Targets , H1 2016 24 Number of Products by Stage and Top 10 Targets , H1 2016 24 Number of Products by Top 10 Mechanis m of Actions , H1 2016 26 Number of Products by Stage and Top 10 Mechanis m of Actions , H1 2016 26 Number of Products by Routes of Adminis tration, H1 2016 28 Number of Products by Stage and Routes of Adminis tration, H1 2016 28 Number of Products by Molecule Types , H1 2016 30 Number of Products by Stage and Molecule Types , H1 2016 30
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349